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Abstract:  The successful control of HBV infection requires an efficient expansion of 
distinct elements of the adaptive immune system (B cells, helper and cytotoxic T cells) 
that, due to the hepatotropic nature of HBV, need to operate in the liver parenchyma. In 
this respect, we will discuss broad features of HBV immunity in patients with resolved or 
chronic HBV infection and analyze how the liver environment can directly modulate HBV-
immunity. 
Keywords: HBV; T cells; B cells 
 
Introduction 
A network of cell types, which can play protective or pathogenic roles, forms the anti-viral adaptive 
immune response during HBV infection. These different components are: a) CD4 T cells, classically 
referred to as helper T cells. They are robust producers of cytokines and are required for the efficient 
development of effector cytotoxic CD8 T cells and B cell antibody production. In addition, CD4 T 
cells can potentially modulate inflammatory events through secretion of pro (CXCL-8, IL-17) or anti-
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inflammatory (IL-10) cytokines. b) CD8 T cells are able to directly recognize virus-infected cells and 
clear HBV-infected hepatocytes through cytolytic and non-cytolytic mechanisms [1, 2], reducing the 
levels of circulating virus. c) B cells can neutralize free viral particles through antibody production to 
prevent (re)infection [3, 4] and might modulate helper T cell function through their ability to present 
HBV antigens (Figure 1). 
Figure 1. Anti-viral adaptive immune response during HBV infection. 
 
The ability to develop and preserve an efficient HBV-specific adaptive immune cell network is 
thought to represent the most important discriminatory factor between HBV control or chronicity   
[5, 6]. Such ability is influenced by events occurring in the initial phases of infection and is related to 
the innate immune response, which will not be covered in this review and has already been extensively 
discussed [7, 8]. In this review we will briefly summarize the different features of adaptive immunity 
in resolved versus chronic patients and the potential causes of the apparent collapse of HBV-immunity 
during chronicity. We will also discuss different variables that can alter virus-specific T cell function 
in the intrahepatic compartment. 
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HBV-adaptive immunity: control versus chronicity 
What is clear in HBV infection is that HBV-specific CD4 and CD8 T cell frequency and function is 
far superior in patients who resolve HBV infection than in subjects with chronic infection. The ability 
of patients who resolve the infection to produce anti-viral cytokines (IFN-γ and TNF-α) results in HBV 
clearance from infected hepatocytes without extensive direct killing [9-20]. The contribution of B cells 
and antibody are also important in HBV control, although these components of adaptive immunity 
have attracted less scientific attention in comparison to T cells. Nevertheless, HBV clearance is 
associated with the production of anti-envelope antibodies [3], and sera with high levels of anti-viral 
antibodies (specific for the viral envelope) can control HBV infection [4].  
A level of coordination between the different components of adaptive immunity seems necessary to 
achieve sustained HBV control. For example, woodchucks infected with WHV (woodchuck hepatitis 
B virus) demonstrate the importance of a coordinated helper and cytotoxic T cell response in 
controlling hepadnavirus infections. It was observed that a reduced early expansion of virus-specific T 
cells during WHBV infection was associated with virus persistence [21]. In patients studied during the 
incubation phase of acute HBV infections, expansion of virus-specific IFN-γ+ CD8 and CD4 T cells 
preceded complete virus clearance and this response was present only in subjects who controlled the 
infection [22]. Furthermore, a recent analysis of HBV-specific T cell responses in an HBV-HCV 
acutely co-infected patient, who developed a persistent HBV infection, showed the presence of a 
multi-specific CD8 T cell response in the absence of a CD4 T cell response [23]. It is likely that the 
absence of CD4 help prevented the maturation of a functionally effective CD8 T cell response.  
Interestingly, the development of functional HBV-specific memory CD8+ T cells is linked to down-
regulation of PD-1 expression (and up-regulation of the IL-7 receptor CD127) on HBV-specific CD8 
cells  [24, 25]. Increased functional activity of the HBV-specific CD8+ T cell response during the late 
stages of acute HBV infection has been previously reported [16], but these new data establish a direct 
link between over-expression of PD-1, functional alteration, and acquisition of functional efficiency. 
We will discuss in the next paragraph how, instead, prolonged over-expression of PD-1 constitutes a 
hallmark of the functionally altered T cells present during persistent HBV infection.  
Since most of these studies have been performed in humans, their observational nature does not 
allow us to firmly assert that T-cell defects observed in chronic HBV patients are the cause or the 
consequence of HBV persistence. However, studies in animal models and clinical observations are 
filling this gap. CD8 T cell deletion experiments performed in HBV-infected chimpanzees have 
provided strong support for the concept that CD8 T cells are responsible for viral clearance [26]. 
Furthermore, chronic HBV patients who underwent bone marrow transplantation and received marrow 
from donors with natural immunity to HBV resolved chronic HBV infection [27, 28, 29]. Similarly, a 
recent report showed HBV clearance from a HBV chronically infected liver that was transplanted into 
a subject with a prior self-limited HBV infection [30]. In both examples, HBV clearance from the 
chronically infected liver was, as in the natural self-limited HBV infection [9, 10], associated with an 
HBV-specific T-cell response and production of anti-envelope antibodies. Taken together, these 
examples suggest that it may be a weak or misdirected immune response that leads to chronic HBV 
infection rather than any property of the virus itself. Reconstitution of the immune system by bone 
marrow transplant or transplanting chronically infected liver into a patient with HBV immunity Viruses 2009, 1                              
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achieved viral clearance [27-30] , suggesting that there was nothing inherently persistent in the virus 
infecting these patients. 
Additional evidence that CD4 and CD8 T-cell responses are accountable for the immunological 
control of HBV are represented by the association of particular HLA class I and class II genetic 
profiles with resolution [31]. Interestingly, HLA class II heterozygosis is associated with HBV 
clearance, supporting the hypothesis that multispecific HBV-specific HLA-class II-restricted T cells 
can protect from HBV persistence [32]. 
Adaptive immunity in chronic HBV infection 
Chronic viral infection alters the quantitative and functional profile of virus-specific immunity. 
Detailed functional studies have mainly focused on the analysis of CD8 T cells, which during 
persistent viral infection lose their ability to lyse, proliferate and produce different cytokines (i.e. TNF-
alpha and IL-2), and only partially maintain the ability to produce IFN-gamma [33]. This dysfunctional 
state, or exhaustion, is characterized by CD8 T cell over-expression of inhibitory receptors (PD-1, Lag-
3 and CTLA-4), major changes in T-cell receptor and cytokine signaling pathways, and altered 
expression of genes involved in adhesion and migration. In addition, exhausted virus-specific T cells 
show profound metabolic and bio-energetic deficiencies [34].  
HBV-specific CD8+ T cells detected during chronic infection often display similar defects. They 
produce low levels of antiviral cytokines, proliferate poorly in vitro, express the inhibitory receptor 
PD-1, and are prone to apoptosis [20, 35]. However, dysfunctional HBV-specific T cells are not the 
classical hallmark of patients with chronic HBV infection. In reality, such a dysfunctional population 
is mainly detectable in the blood of chronic HBV patients with low level of HBV-replication (around  
< 0.5-1 x 10
6 HBV-DNA IU/mL) and HBV-specific T cells are often undetectable in the majority of 
patients with higher levels of HBV replication (HBeAg+, HBV-DNA IU/mL > 0.5-1 x 10
8). T cells 
specific for HBV antigens that are more expressed in the liver are deleted in HBV transgenic mice 
[36], and the hierarchy of epitope-specific CD8+ T cells is altered in proportion to the level of HBV 
DNA in chronically infected patients. For example, CD8 T cells, specific for a dominant core epitope, 
cannot be found in the circulation or liver when HBV viremia exceeds 0.5-1 x 10
7 copies/mL [18]. 
Importantly, the deletion/alteration of HBV-specific cells is not limited to the cellular arm of 
immunity, but also affects the humoral response, as HBV-specific antibody production is clearly 
impaired in chronic patients [37]. 
We believe that the prolonged exposure to large quantities of soluble HBV antigens (HBsAg and 
HBeAg) and the tolerogenic features of the liver are the principal causes of the functional alteration 
and deletion of virus-specific B and T cells present in chronic HBV patients. Antigen persistence alters 
T-cell function and causes deletion in different viral infections [38]. In HBV infection, the immune 
system has to handle unusually high quantities of viral antigens. HBeAg, a secretory form of the HBV 
nucleocapsid, or core antigen, is produced during HBV replication. The tolerizing effect of HBeAg has 
been well characterized in mice and is likely contributing to the low level of core-specific T-cell 
responses present in chronic HBV patients. HBsAg is also produced in large excess during HBV 
infection. Particles composed of only HBsAg are produced in 10
3-10
6 fold excess over whole virions 
and can reach 1-10 ug/mL in the serum [39]. Viruses 2009, 1                              
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Such a high and persistent load of viral antigens allows them to be cross-presented by liver 
professional antigen-presenting cells (Kuppfer cells, liver endothelial cells), which can have a 
tolerizing effect [40, 41]. This might well explain the level of the T cell hyporesponsiveness present in 
HBV chronic patients. In addition, direct presentation of foreign antigen by hepatocytes has been 
suggested to preferentially induce tolerance in CD8 T cells, reducing T cell expansion and promoting 
T cell apoptosis [42-44]. However, this scenario is still controversial since other work in mice has 
shown rapid activation and expansion of naïve and effector CD8 T cells following hepatocyte 
presentation of viral antigen [45]. 
Additional factors might contribute to the maintenance, if not directly induce, HBV-specific 
immune dysfunction. Some could exert their function mainly in the intrahepatic environment, while 
others are not topologically restricted to the liver (Table 1). Regarding the latter, we include dendritic 
cell functional alteration and T regulatory cells. Dendritic cells represent a specialized antigen-
presenting cell population necessary for the efficient induction of an adaptive immune response [46]. 
We think that the evidence for an impact of altered dendritic cell function in causing and/or 
maintaining the HBV-specific immune defects during chronic HBV infection is fragile. Dendritic cells 
can be infected in animal models of hepadnavirus infection [47], but productive HBV replication in 
dendritic cells has recently been excluded in chronic hepatitis B patients [48, 49], and the stimulatory 
defects observed seem minimal [50-53]. A recent report described an up-regulation of PD-L1 on 
myeloid dendritic cells of chronic HBV patients, suggesting a generalized T cell inhibitory effect of 
the PD-1/PD-L1 interaction mediated by dendritic cells [54]. These data would imply a global 
impairment of the immune system which is not evident from a study performed on a large group of 
chronic HBV patients of different ethnicities [55]. 
Table 1. Mechanisms regulating function of HBV-specific T cell immunity. 
Broad - Not organ specific  Liver specific 
High dose of antigen-  Metabolic feature of the liver 
(Arginase) 
Reduced pro-inflammatory 
cytokine production. 
Dendritic cells impairment /  
Hepatocytes presentation (inhibitory 
molecules / HLA-class I) 
T regulatory cells  Interaction with other cells 
(i.e.Platelets-granulocytes) 
 
The impact of T regulatory cells in the modulation of HBV-specific T cell immunity is also 
controversial (see also [56, 57]). Treg cells are diverse, occurring in both CD4 and CD8 T cell subsets. 
They express various markers such as CD25 (IL-2 receptor α chain), cytotoxic T-lymphocyte antigen 4 
(CTLA-4) and the forkhead family transcription factor (FoxP3) [58], and can potentially suppress anti-
HBV immunity through cell to cell contact or production of regulatory cytokines like IL-10 [59]. 
Studies have reported an increased frequency of circulating regulatory cells in all patients with chronic 
hepatitis B [60], but others either found that this quantitative correlation was only present in patients 
with severe disease or could not confirm such data [61, 62]. Similar inconsistencies were detected 
when Treg cell frequency was analyzed in relation to viral load [57] and when the functionality of Treg Viruses 2009, 1                              
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cells was examined. Depletion of CD4+CD25+ cells increased the function of HBV-specific T cells 
[62, 63, 64] in vitro, but such modulation was HBV-specific for some [63], but not others [62].  
We think it is important to consider that these studies were limited to the analysis of the CD4+ 
CD25+ cells present in the blood, while a detailed analysis of the intrahepatic frequency and function 
of these cells has not been performed. Furthermore, it is possible that a population of HBV-specific 
regulatory cells, different from the CD4+ CD25+ T cell subset, analogous to the presence of IL-10-
producing HCV-specific T cells [65], might be present in chronic HBV infection. There have been 
initial reports of the presence of such HBV-specific IL-10-producing Treg in patients with chronic 
hepatitis [66, 67], but the frequency of such cells appears extremely low and could not been confirmed 
in more recent analysis (Gehring, A.; Bertoletti, A. Manuscript in preparation). 
T cell response and function within the liver 
We have discussed the features of adaptive immunity in patients with chronic and resolved HBV 
infection and the potential mechanisms that are likely to affect their quantitative and qualitative profile. 
A final issue that we would like to briefly discuss is the modulation of effector T cell function caused 
by the liver environment. This aspect is different from the tolerogenic features of the liver which act on 
the induction phase, and instead deals with the potential direct influence of liver environment and 
hepatocyte antigen presentation on T cell effector function. 
The fact that virally infected hepatocytes are largely resistant to perforin/granzyme-mediated killing 
[68], but highly sensitive to cytokine-mediated clearance of HBV [69], illustrates how T cell effects 
can be different in the liver environment. However, new aspects such as modulation of T cell function 
induced by hepatocyte antigen presentation [70], metabolism in the liver environment with the ability 
of Arginase to alter CD3 zeta expression on T cells [71], and the interaction with other cell types (i.e. 
platelets) [72, 73], have recently been reported in the scientific literature.  
Isogawa et al. have shown in an in vivo model of HBV infection that effector T cells can change 
their cytolytic or non-cytolytic function after recognition of antigen presented by hepatocytes [70]. 
Their data show oscillation of effector T cell function, which mainly produce cytokines when initially 
triggered by a high dose of HBV antigens and then switch their function toward a restricted cytolytic 
effect. This functional swing might be regulated by the expression of PD-1 on effector cells [74] or be 
a direct consequence of antigen dose [70]. Both hypotheses are in agreement with human data. PD1 
and PD-L1 interaction can occur in the liver, since PD-L1 is expressed by infected hepatocytes [75]. 
On the other hand, recent analyses performed in vitro using human CTL clones and T cell effector 
lines have shown that the quantity of viral antigen presented by hepatocytes can influence CD8 T cell 
anti-viral function. High levels of HBV production induced robust IFN-γ production in virus-specific 
CD8 T cells, while limiting amounts of viral antigen, both in hepatocyte-like cells and naturally 
infected human hepatocytes, preferentially stimulated CD8 T cell degranulation [76].  
The possibility that increased availability of MHC-viral peptide complexes on hepatocytes, as a 
consequence of different levels of HBV replication, could trigger differential function in HBV-specific 
T cells is consistent with clinical and new experimental observations. Hepatic flares are associated 
with increased levels of HBV replication (> 10
7 copies/mL serum), while chronic patients that control 
HBV replication (< 10
6 copies/mL serum) can do so without signs of liver inflammation. In both 
situations, the quantity of intrahepatic HBV-specific CD8+ T cells are similar and the discriminatory Viruses 2009, 1                              
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factor is the level of HBV replication, suggesting that the availability of antigen modulates T cell  
function [76].  
The concept that effector T cells can modulate their function in relation to different levels of 
hepatocyte antigen presentation is further supported by recent observations that classical Th1/Tc1 
HBV-specific T cells can produce the neutrophil chemotactic factor CXCL-8 when stimulated by high 
antigen dose. Parenchymal recruitment of granulocytes is a common step of immunopathological 
processes triggered by CTLs during infection with non-cytopathic viruses [77], and seems particularly 
important in the liver, where intra-hepatic neutrophil activation digests collagen and opens the liver 
parenchyma for inflammatory mononuclear cell infiltration [78, 79]. 
The cross-talk between different components of immunity, like the ability of HBV-specific T cells 
to produce chemokines involved in the recruitment of granulocytes, opens a further chapter; the 
influence of other cell types on the function of adaptive immunity in the liver. Work on HBV 
transgenic mice has clearly shown that activated platelets influence the recruitment of virus-specific 
CTLs into the liver [72]. Platelet depletion reduced intrahepatic accumulation of virus-specific CTLs 
and liver damage without impairing the effector functions of CTLs. Such results were obtained both in 
HBV transgenic [80] and LCMV-infected mice [73]. The specific interaction between activated 
platelets and virus-specific CTLs seems to favor their accumulation at the site of inflammation, a 
process mediated by serotonin. 
Thus, protective or pathogenic effects of HBV-specific T cells in the liver are not only dependent on 
their quantity and intrinsic function, but can be modulated by external factors like platelets and 
granulocytes. In addition to these data, a recent report by Das et al. has shown that depletion of 
arginine in the inflamed liver can directly interfere with intrahepatic T cell function, particularly with 
their ability to produce IL-2 and proliferate [71]. This adds a further layer of complexity in T cell 
effector function in an HBV-infected liver and the balance between control of HBV infection or 
chronicity.  
Concluding remarks 
Beyond the well characterized differences in HBV adaptive immunity of resolved and chronic 
patients lie a number of issues that have been difficult to determine. We know that the host response to 
HBV infection is a complex coordinated process and that the liver environment might tune effector T 
cell function. Studies have begun to shed light on the peculiarity of the intrahepatic environment and 
how this can modulate virus-specific immunity. In fact, modification of the liver environment may 
already be the basis of the therapeutic effect of IFN-alpha that, through activation of the 
immunoproteasomes in hepatocytes, can change the quantity of HLA-class I/peptide complexes 
available for CD8+ T cell recognition. These types of questions are exceedingly difficult to study in 
humans but it is necessary to understand how the immune system operates in the liver if 
immunotherapeutic strategies under development are to have any success in achieving sustained viral 
control.  
In addition to the liver environment, a better understanding of how the network of immune cells, 
parenchymal/non-parenchymal cells, and platelets interact and communicate to achieve HBV clearance 
or liver damage is critical. Multiple components are involved in each process and being able to 
separate protective from inflammatory processes could increase the efficacy and safety of HBV Viruses 2009, 1                              
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treatment. As a further and final note, the study of HBV-specific adaptive immunity in patients is 
heavily skewed towards analysis of T cell function. Although there is no doubt that T cells play an 
essential role during HBV infection, perhaps new exciting revelations of HBV pathogenesis will derive 
from new accurate studies of HBV-specific B cell function. 
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